US Bancorp DE Buys 14,698 Shares of OraSure Technologies, Inc. (NASDAQ:OSUR)

US Bancorp DE boosted its position in OraSure Technologies, Inc. (NASDAQ:OSUR) by 310.4% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 19,433 shares of the medical instruments supplier’s stock after buying an additional 14,698 shares during the period. US Bancorp DE’s holdings in OraSure Technologies were worth $70,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in OSUR. Principal Financial Group Inc. grew its stake in OraSure Technologies by 10.7% in the fourth quarter. Principal Financial Group Inc. now owns 73,137 shares of the medical instruments supplier’s stock valued at $264,000 after acquiring an additional 7,077 shares during the period. Atom Investors LP acquired a new stake in OraSure Technologies in the 3rd quarter valued at $49,000. Connor Clark & Lunn Investment Management Ltd. increased its stake in OraSure Technologies by 78.2% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 28,731 shares of the medical instruments supplier’s stock valued at $123,000 after purchasing an additional 12,604 shares in the last quarter. Jane Street Group LLC raised its holdings in OraSure Technologies by 6.4% during the third quarter. Jane Street Group LLC now owns 296,194 shares of the medical instruments supplier’s stock worth $1,265,000 after buying an additional 17,758 shares during the last quarter. Finally, Empowered Funds LLC lifted its stake in shares of OraSure Technologies by 5.1% in the fourth quarter. Empowered Funds LLC now owns 377,906 shares of the medical instruments supplier’s stock valued at $1,364,000 after buying an additional 18,487 shares in the last quarter. 93.50% of the stock is owned by institutional investors.

OraSure Technologies Price Performance

OSUR opened at $3.57 on Tuesday. OraSure Technologies, Inc. has a 1 year low of $2.69 and a 1 year high of $6.96. The company has a market capitalization of $267.04 million, a price-to-earnings ratio of 23.80 and a beta of -0.02. The firm’s fifty day moving average price is $3.73 and its two-hundred day moving average price is $3.93.

Analyst Ratings Changes

Separately, StockNews.com cut shares of OraSure Technologies from a “buy” rating to a “hold” rating in a research report on Tuesday, March 4th.

Insiders Place Their Bets

In other OraSure Technologies news, Director John P. Kenny bought 47,659 shares of OraSure Technologies stock in a transaction dated Thursday, February 27th. The stock was bought at an average cost of $3.17 per share, with a total value of $151,079.03. Following the completion of the acquisition, the director now directly owns 70,915 shares in the company, valued at approximately $224,800.55. The trade was a 204.93 % increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CFO Kenneth J. Mcgrath purchased 64,000 shares of the firm’s stock in a transaction that occurred on Thursday, February 27th. The shares were acquired at an average cost of $3.15 per share, with a total value of $201,600.00. Following the completion of the transaction, the chief financial officer now directly owns 371,013 shares of the company’s stock, valued at $1,168,690.95. The trade was a 20.85 % increase in their position. The disclosure for this purchase can be found here. In the last ninety days, insiders bought 190,284 shares of company stock valued at $600,348. Corporate insiders own 3.40% of the company’s stock.

OraSure Technologies Company Profile

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company’s products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.